Background/objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in treating type 2 diabetes and obesity, offering established metabolic and cardiovascular benefits. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.